A technique to investigate microvascular mural thrombus formation in arteries and veins: II. Effects of aspirin, heparin, r-hirudin, and G-4120.

Abstract

After a standardized trauma to carotid arteries or femoral veins of hamsters, the antithrombotic effects of two antiplatelet agents (aspirin and the glycoprotein IIb/IIIa antagonist G4120) and two anticoagulants (heparin and the direct thrombin inhibitor r-hirudin) were studied in vivo. The thrombus area volume was assessed by image analysis of the transilluminated experimental vessels. Heparin, r-hirudin, and G-4120 demonstrated a dose-dependent complete inhibition of arterial and venous thrombosis. In contrast, the antithrombotic effect of aspirin was only partial in both vessel types. A significant correlation between activated partial thromboplastin time (aPTT) at the end of the experiments and the antithrombotic effect was observed with the anticoagulant agents. However, only r-hirudin inhibited thrombus formation at a therapeutical prolongation of aPTT, while heparin required supratherapeutical amounts to achieve the same inhibition. The data confirm that the inhibition of aspirin, heparin, r-hirudin, and G-4120 on the formation of platelet-rich thrombi is independent of the blood flow rate.

• Authors: F Stockmans, J M Stassen, J Vermylen, M F Hoylaerts, A Nyström
• Journal: Annals of plastic surgery (Ann Plast Surg) Vol. 38 Issue 1 Pg. 63-8 (Jan 1997) ISSN: 0148-7043 [Print] United States
• PMID: 9015542 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Anticoagulants
• Peptides, Cyclic
• Platelet Aggregation Inhibitors
• Sulfoxides
• G 4120
• Heparin
• Aspirin

Topics

• Animals
• Anticoagulants (therapeutic use)
• Aspirin (therapeutic use)
• Carotid Artery Thrombosis (etiology, prevention & control)
• Cricetinae
• Disease Models, Animal
• Dose-Response Relationship, Drug
• Femoral Vein
• Heparin (therapeutic use)
• Hirudin Therapy
• Linear Models
• Male
• Partial Thromboplastin Time
• Peptides, Cyclic (therapeutic use)
• Platelet Aggregation Inhibitors (therapeutic use)
• Sulfoxides (therapeutic use)
• Thrombosis (etiology, prevention & control)